Aug 2026· Journal of Clinical Investigation· 0 citations
Medicine
TL;DR
It is shown that increased ovarian area contributes to both PMOS susceptibility and ovarian cancer progression, while specific ovary-heart signaling circuits modulate cardiac function with aging, and SF3B1-mediated splicing is uncovered as a link between ovary function and systemic metabolism.
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is the most common endocrine disorder in women and is closely associated with complex diseases such as cardiovascular disease and type 2 diabetes. However, the mechanistic links between PMOS and its comorbidities remain poorly understood. Here, we present an integrative systems genetics platform that leverages genetic diversity in both mice and humans to dissect the drivers of PMOS and its associated complications. This framework uncovers conserved genetic and environmental factors underlying PMOS, identifies susceptible cell types and organs, and elucidates mechanisms linking PMOS to subsequent pathologies. For instance, we show that increased ovarian area contributes to both PMOS susceptibility and ovarian cancer progression, while specific ovary-heart signaling circuits modulate cardiac function with aging. We further identify ovarian SF3B1-mediated alternative splicing as a key mechanistic link between PMOS and metabolic traits. Pharmacologic inhibition of SF3B1 in mice reduced circulating testosterone, insulin and glucose levels, as well as fat mass expansion. Transcriptomics analysis of ovaries from mice and experiments using human cell lines localized these effects to exon skipping events in granulosa cells. Together, this study offers a mechanistic framework for modeling the diversity of PMOS pathologies and uncovers SF3B1-mediated splicing as a link between ovary function and systemic metabolism.
Recognizing PMOS as an early-life marker of cardiometabolic disease highlights opportunities for earlier diagnosis, prevention, and individualized risk stratification, supporting integrated, patient-centered care across the life course.
M. Forslund, J. Melin, A. Joham et al.· Journal of Internal Medicine· 0 citations
A comprehensive and personalized therapeutic approach integrating pharmacological, lifestyle, and microbiome-targeted interventions may significantly improve PCOS management and reduce long-term metabolic and reproductive complications.
J. Singla, Shubhi Yadav, J. Gayen· Journal of Reproductive Immu...· 0 citations
Understanding enzyme-level dysregulation offers opportunities for mechanism-based interventions that can restore steroidogenic homeostasis, improve fertility outcomes, and mitigate long-term metabolic risk in PCOS.
Thirumurugan Ayyadurai, S. Ravi, Aravinth Annamalai· Journal of Steroid Biochemis...· 1 citation
It is suggested that PMOS is not characterized by major gut microbiome shifts but may involve subtle depletion of health-associated commensals and increased microbial heterogeneity.
Loida A. González-Rodríguez, Keishla M. Jimenez-Ortega, D. Vargas-Robles et al.· Frontiers in Endocrinology· 0 citations
A novel EDC-CBX2-H3K27me3 epigenetic axis that decouples GC proliferation from metabolic support functions is revealed, establishing CBX2 as both a molecular biomarker and potential therapeutic target for environment-associated PCOS.
Chan Zhu, Xian-Liang Qiu, Hong Yang et al.· Journal of Steroid Biochemis...· 0 citations
A narrative review synthesizes evidence at the intersection of developmental biology, genomic architecture, and epigenetics to delineate how dysregulated ovarian developmental pathways contribute to PCOS pathogenesis.
Ayşegül Karahanoğlu, M. Ozer, Y. Terzi et al.· Medical Science and Discover...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.